Steven L. Hoerter - Mar 21, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role: President and CEO, Director
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol: DCPH
Transactions as of: Mar 21, 2023
Transactions value $: -$116,782
Form type: 4
Date filed: 3/23/2023, 04:05 PM
Previous filing: Feb 16, 2023
Next filing: Jun 15, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Sale	-$117K	-7.5K	-100%	$15.57	0	Mar 21, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units ("RSUs") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.395 to $15.70, inclusive. The Reporting Person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units ("RSUs") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.395 to $15.70, inclusive. The Reporting Person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.